(PPBT) Purple Biotech Ltd. Business Model Canvas Research

Purple Biotech Ltd. relies on GMP partners because CM24 is a monoclonal antibody and NT219 is a small molecule, so both need tight drug substance, drug product, packaging, and release testing control. For 2025/2026-stage Phase 1b/2 and Phase 1/2 supply, one missed batch can delay dosing and push trial timelines by months.

• 2 clinical assets need distinct GMP workflows

• Partners cover making, packing, and release tests

• Supply continuity protects Phase 1b/2 and Phase 1/2 dosing

Purple Biotech Ltd. works with academic oncology investigators because its pipeline targets immune evasion and drug resistance in hard-to-treat solid tumors, where translational insight matters. These investigators add patient access, clinical reading, and stronger trial design, which can also lift publication quality and speed outside validation.

• Sharper translational trial design
• Access to hard-to-reach patients
• Better clinical interpretation
• Higher publication and credibility potential

For Purple Biotech Ltd., this partnership is practical: academic sites help test biomarkers and response signals in real patients, which is critical when oncology programs depend on small, high-need cohorts. That mix can improve data quality and reduce the risk of weak, hard-to-interpret readouts.

Regulatory and ethics submissions keep Purple Biotech Ltd.'s oncology studies active by filing protocol amendments, safety reports, and regulator updates on time. This is a nonstop task in early-stage development, where even one delayed ethics approval can pause patient dosing or site activation.

• Protocol changes filed fast
• Safety events reported continuously
• Approvals maintained across studies

Purple Biotech Ltd. must keep raising capital to fund its clinical R&D, since trial work, CMC, and regulatory steps burn cash before product revenue arrives. Investor updates, SEC filings, and market messaging help sustain access to public equity financing, which remains a core activity for a clinical-stage biotech.

• Funds R&D until revenue
• Uses SEC reporting for trust
• Supports equity financing access

Purple Biotech Ltd.’s clinical data package is anchored by early human readouts from CM24 and NT219, its two lead oncology assets. Safety, pharmacology, and tumor response signals drive go/no-go calls and give larger cancer companies the evidence they need for partnering.

• CM24 and NT219 are the core data assets.
• Safety and PK guide development choices.
• Response signals support partnership talks.

Purple Biotech Ltd., based in Rehovot, Israel, relies on a small scientific and management team to run oncology R&D, clinical development, CMC, and capital-markets work because it has no commercial sales force. For a clinical-stage company, that human know-how is the core asset, not a field team.

• Oncology and trial design
• CMC and quality control
• Capital-markets access
• No sales force

Purple Biotech’s value lies in two clinical-stage assets with different mechanisms: a monoclonal antibody and a small molecule. That split can reach different tumor biology and reduce dependence on one program; as of the latest public filings, the Company still has just 2 clinical assets, so each readout matters.

• Two assets, two mechanisms
• Broader tumor coverage
• Lower single-asset risk

Purple Biotech Ltd.'s pipeline spans non-small cell lung cancer, pancreatic cancer, recurrent or metastatic solid tumors, and squamous cell carcinoma of the head and neck, covering markets with very high unmet need. Lung cancer alone caused about 2.5 million new cases worldwide in 2022, while pancreatic cancer had about 511,000, so broad indication reach can improve partnering appeal.

• Targets multiple large oncology markets
• Fits high-unmet-need settings
• Improves partnering flexibility

Purple Biotech Ltd. relies on larger oncology and biotech partners to advance assets, with talks centered on data access, development rights, and commercial split. These deals are typically transaction-based and milestone-driven, so value depends on preclinical and clinical readouts, not repeat buying.

• Partner-led, milestone-based model
• Focus: data, rights, commercial terms
• Best fit: larger oncology partners

Patients engage with Purple Biotech Ltd mainly at clinical trial sites, where site staff handle informed consent, dosing visits, and follow-up. This matters because Purple Biotech Ltd has no marketed products, so patient trust and retention depend on the site team, not on a commercial brand.

• Site staff own the patient relationship
• Consent, dosing, and follow-up happen onsite
• No marketed products means no direct brand channel

Purple Biotech Ltd. uses its corporate website and press releases as its core public-disclosure channels. Press releases flag trial milestones, financing events, and corporate updates, while the website supports investors, partners, and the scientific community; as a Nasdaq-listed company (PPBT), this is the main source for timely public news.

• Trial milestones
• Financing updates
• Investor and partner access
• Scientific updates

Purple Biotech Ltd. uses direct outreach to institutional investors and strategic partners to fund its clinical pipeline and secure licensing talks. As a clinical-stage, pre-revenue company, this channel matters more than product sales: it can bring in capital and partnership cash before any approved product reaches market.

• Direct investor contact supports financing
• Partner talks can trigger licensing income
• Critical for pre-revenue biotech scale-up

Head and neck squamous cell carcinoma is Purple Biotech Ltd.’s clear niche: HNSCC makes up about 90% of head and neck cancers, with roughly 890,000 new cases and 450,000 deaths worldwide in 2022. NT219’s Phase 1/2 program targets a high-need solid-tumor group, so early data can guide expansion.

• Distinct solid-tumor patient base
• High unmet need, large burden
• Phase 1/2 readout can scale use

As a pre-commercial biotech, Purple Biotech Ltd. sells to oncology pharma partners and investors, not patients. Partners can license or co-develop assets, while investors fund R&D and keep the pipeline alive; this segment mix is the core economic engine before any product revenue exists.

In practice, these buyers care about clinical proof, deal terms, and cash runway. A clean one-liner: no partner or capital, no pipeline.

• Partners fund via licenses or co-development
• Investors back clinical-stage risk
• Pipeline value depends on trial data

Patent maintenance, outside counsel, and regulatory filings are recurring, not one-off, costs for Purple Biotech Ltd.; in biotech, even one patent family can require six-figure annual upkeep across key markets. Public-company compliance adds more fixed spend for audits, SEC filings, and governance, so these costs help protect trial assets but also pressure cash burn.

• Patent upkeep: recurring, six-figure risk
• Legal + regulatory work: continuous
• Public listing: audit and filing burden

Purple Biotech Ltd. keeps general and administrative overhead tied to a small public biotech model: finance, HR, IT, legal, and exchange reporting stay necessary, but office and admin spend should sit below R&D. That setup fits a development-stage Company Name with lean staff and recurring public-company costs.

• Public-company reporting is fixed cost
• Admin spend stays lean vs. R&D
• Small headcount keeps overhead controlled

For Purple Biotech Ltd., royalties on future sales can turn a licensing deal into recurring cash if an asset reaches market; biotech deals often use single-digit to low-teens percentages of net sales, so one approved drug can matter more than upfront fees. For a small biotech with no steady product revenue, that long-tail upside is a key value driver.

• Linked to net sales, not fixed fees
• Creates upside after approval
• Fits small biotech cash needs

Purple Biotech Ltd. funds R&D mainly through public equity offerings and other capital raises, plus non-dilutive funding such as research grants or partner payments. This matters because the company has no product revenue yet, so these inflows are the cash bridge that keeps trials and development moving.

• Equity raises fund operations.
• Non-dilutive funding cuts dilution.
• Cash supports pre-revenue R&D.